Jessica Stempel
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Year:
2026
Year:
2026
Year:
2026
PURPOSE Women occupy a minority of academic leadership positions despite increasing representation in the physician workforce. Similarly, women remain underrepresented as academic conference presenters, an important factor for career advancement. We examined whether there were gender disparities in opportunities to present original research at the ASCO Annual Meeting. METHODS We retrospectively reviewed oral original research, educational, and discussant presentations at the ASCO Annual Meetings from 2018 to 2021. Presenters were identified as first author, senior author, or ASCO-appointed (chair, discussant, or speaker). Presenter-identified gender was unavailable; binary gender was determined by presenter name, pronouns, video files, and institutional websites. Presenter gender distributions were summarized descriptively by nominal levels for each third variable with corresponding odds ratios (ORs) for each nominal level. Common ORs were estimated for each third variable if the Breslow-Day test was not significant, with no adjustments for P values. RESULTS We reviewed 4,267 video presentations, divided into original research (n = 2,079) and ASCO-appointed (n = 2,188). Women represented 37% of first authors (OR, 0.68 [95% CI, 0.60 to 0.76]) and 28% of senior authors (OR, 0.44 [95% CI, 0.39 to 0.50]), compared with 47% of ASCO-appointed presenters. Women were significantly more likely to have an ASCO-appointed role than a first or senior author role, even after adjusting for conference year, session type, session area, academic rank, and geographic region. CONCLUSION Gender disparities persist in opportunities to present original research at the ASCO Annual Meeting. Women were less likely to present research as first or senior author and were more likely to have an educational or discussant role. As high-profile original research can elevate careers, examining factors contributing to this disparity may suggest approaches to address gender leadership gaps in oncology.
Year:
2026
Luspatercept has emerged as a novel therapy for anemia in transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS). This systematic review and meta-analysis aimed to evaluate the efficacy and safety of luspatercept in TD LR-MDS. Six databases were searched through March 2025 to find relevant material. Studies were screened and extracted by 2 independent authors. A total of 20 studies encompassing 3455 patients were included in the analysis. The pooled 8-week transfusion independence (TI) rate was 51.2% (95% confidence interval [CI], 39.9-60.4; I2 = 94.9%), with higher rates observed among ring sideroblast–positive (RS+) patients (57.8%; 95% CI, 47.4-67.7; I2 = 86%) and those with low transfusion burden (LTB; 72.9%; 95% CI, 60.4-82.6; I2 = 0%). The 12-week and 24-week TI rates were 57.0% (95% CI, 48.1-65.5; I2 = 90%) and 35.8% (95% CI, 28.7-43.6; I2 = 82.1%), respectively. Hematologic improvement–erythroid was achieved in 51.3% of patients (95% CI, 41.3%–61.2%; I2 = 93%). The most frequent adverse events were peripheral edema (17.8%; 95% CI, 11.4-26.8), diarrhea (15.6%; 95% CI, 8.2-27.7), and fatigue (11.4%; 95% CI, 5.4-22.6). Serious adverse events occurred in 28.0% of patients (95% CI, 12.8-50.7; I2 = 97.2%). Luspatercept is an effective and well-tolerated treatment for anemia in TD LR-MDS, especially in patients with RS+ and LTB. Its favorable safety profile and high TI rates, particularly in erythropoiesis-stimulating agent–naïve populations, support its use in the frontline setting.
Year:
2025
Year:
2025
The ETAL-1 trial demonstrated that upfront allogeneic hematopoietic stem cell transplant (HSCT) improved disease-free survival, but not overall survival, when compared with consolidation chemotherapy followed by “delayed” HSCT on relapse in patients with intermediate-risk acute myeloid leukemia (AML). However, the health-economic implications of upfront HSCT compared with delayed HSCT are unknown. We developed a partitioned survival analysis model using derived survival data, probabilities of salvage treatments, utilities, and costs from the ETAL-1 trial and published literature. The primary outcome was the incremental net monetary benefit (INMB) from the perspective of the United States and United Kingdom health care systems, at all accepted willingness-to-pay (WTP) thresholds: $50 000 to $150 000 per quality-adjusted life year (QALY), and £20 000 to £30 000 per QALY, respectively. The respective INMBs favored upfront HSCT, and were $497 100 (95% confidence interval [CI], $259 800-$719 600) and £235 600 (95% CI, £166 800-£298 500) at WTP thresholds of $150 000 per QALY and £30 000 per QALY. Across deterministic sensitivity analyses, no model input changed the conclusion that upfront HSCT is the cost-effective strategy in either jurisdiction. Probabilistic sensitivity analysis showed that upfront HSCT was cost-effective in 100% of iterations, and was less costly and more effective (ie, “dominant”) in >90% of iterations in both health care systems. In conclusion, we conducted a partitioned survival analysis based on the ETAL-1 trial, and showed that proceeding to HSCT in first remission is the cost-effective strategy in the care of patients with intermediate-risk AML in both the United States and the United Kingdom, as compared with delayed HSCT.
Year:
2025
Myelodysplastic syndromes/neoplasms (MDS) represent a biologically and clinically diverse group of myeloid malignancies marked by cytopenias, morphological dysplasia, and an inherent risk of progression to acute myeloid leukemia. Over the past two decades, the field has made significant advances in characterizing the molecular landscape of MDS, leading to refined classification systems to reflect the underlying genetic and biological diversity. In 2025, the treatment of MDS is increasingly individualized, guided by integrated clinical, cytogenetic, and molecular risk stratification tools. For lower-risk MDS, the treatment paradigm has evolved beyond erythropoiesis-stimulating agents (ESAs) with the introduction of novel effective agents such as luspatercept and imetelstat, as well as shortened schedules of hypomethylating agents (HMAs). For higher-risk disease, monotherapy with HMAs continue to be the standard of care as combination therapies of HMAs with novel agents have, to date, failed to redefine treatment paradigms. The recognition of precursor states like clonal hematopoiesis of indeterminate potential (CHIP) and the increasing use of molecular monitoring will hopefully enable earlier intervention/prevention strategies. This review provides a comprehensive overview of the current treatment approach for MDS, highlighting new classifications, prognostic tools, evolving therapeutic options, and ongoing challenges. We discuss evidence-based recommendations, treatment sequencing, and emerging clinical trials, with a focus on translating biological insights into improved outcomes for patients with MDS.
Year:
2025
Background: Acquired aplastic anemia (AA) is rare bone marrow failure syndrome characterized by pancytopenia due to immune-mediated destruction of hematopoietic stem and progenitor cells, and leads to an increased risk of bleeding and infectious complications. The first-line treatment option for individuals with severe AA who are ineligible for allogeneic hematopoietic stem cell transplantation is triple therapy, comprised equine anti-thymocyte globulin, calcineurin inhibitor (CNI), and eltrombopag (EPAG). However, this approach is associated with considerable treatment-related complications, requires close inpatient monitoring as well as specialized care and expertise, limiting its feasibility in less-experienced centers. Emerging evidence suggests that double therapy with CNI and EPAG combination reduces the transfusion burden in severe AA. Objective: Evaluate the real-world effectiveness of CNI and EPAG combination therapy in reducing transfusion burden among adults with AA. Methods: We conducted a retrospective cohort study using Blue Cross Blue Shield Axis Database to examine the change in transfusion requirements in adult patients with newly diagnosed AA who have received combination therapy with CNI and EPAG. Individuals were stratified into baseline transfusion-independent, low, and high transfusion subgroups. Transfusion requirements were reassessed after 6 months from initiation of double therapy. Results: The majority of the 153 identified patients with AA started therapy shortly after diagnosis and were adherent to treatment and monitoring during the initial 6 months. Among patients with baseline transfusion requirements (97; 63.4%), 66% achieved TI status. Additionally, 75.5% of patients with a high baseline transfusion burden demonstrated a ⩾50% reduction in transfusion requirements. Conclusion: These findings underscore the efficacy and feasibility of double therapy with CNI and EPAG for adults with AA in the real-world setting, offering an alternative for patients when triple therapy is not possible.
Year:
2025
Acquired aplastic anemia (AA) is an immune-mediated disorder leading to bone marrow failure characterized by pancytopenia, with infectious and bleeding complications. The disease course may be complicated by paroxysmal nocturnal hemoglobinuria (PNH), necessitating screening with flow cytometry (FC) at the time of AA diagnosis. Management strategies vary based on disease severity. Severe AA patients are usually heavily transfusion-dependent (HT-AA) and typically treated with antithymocyte globulin, calcineurin inhibitor (CNI) and eltrombopag (EPAG) as triple therapy, while allogeneic hematopoietic stem cell transplant (HSCT) is often reserved for younger patients with matched sibling donors. Moderate AA patients are less transfusion-dependent (LT-AA) and may be observed or treated with CNI or EPAG. We conducted a retrospective cohort study using Blue Cross Blue Shield Axis database, examining adult patients diagnosed with AA between 07/01/2016 and 06/30/2022. We evaluated their management within the first 6 months following the diagnosis. Of 793 identified individuals (542 LT-AA, 251 HT-AA), with a median age of 49 years, only 42.6% received AA-directed therapy. Triple therapy and HSCT were infrequently used for patients with HT-AA (4.4% and 18.7%, respectively), while the most common treatment was the combination of a CNI and EPAG (LT-AA 37.8%, HT-AA 51.7%). The median time from diagnosis to treatment was 22 days, with older patients (age ≥ 40 years) experiencing treatment initiation delays ( p = 0.03). FC testing was underutilized with only 55.5% of patients undergoing evaluation. These findings highlight the need for better access to diagnostic evaluation and appropriate AA-directed therapy for patients with AA in real-world settings.
Year:
2025
Year:
2024
Year:
2024
Collaborators (6)
Geoffrey Uy
Professor of Medicine
Washington University School of Medicine
Benjamin Rolles
Stanford University
Luca Lanino
Yale University
Allison Betof Warner
Assistant Professor, Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy
Stanford University
Scott F Huntington
Yale University School of Medicine
Nikolai A. Podoltsev
Yale University
Make your next move.
Prepare your application
Review drafts before you send them.